Intraocular delivery considerations of ocular biologic products and key preclinical determinations.

Hughes, Patrick; Rivers, Hongwen M; Bantseev, Vladimir; Yen, Chun-Wan; Mahler, Hanns-Christian; Gupta, Swati

Hughes, Patrick; Rivers, Hongwen M; Bantseev, Vladimir; Yen, Chun-Wan; Mahler, Hanns-Christian; Gupta, Swati.

Afiliación

Hughes P; Pharmaceutical Development, Visus Therapeutics, Irvine, CA, USA.
Rivers HM; Biomaterials and Drug Delivery, Medical Aesthetics, AbbVie Inc, North Chicago, IL, USA.
Bantseev V; Department of Safety Assessment, Genentech, Inc, South San Francisco, CA, USA.
Yen CW; Department of Safety Assessment, Genentech, Inc, South San Francisco, CA, USA.
Mahler HC; Ten23 Health Ag, Basel, Switzerland.
Gupta S; Non-clinical Development Immunology, AbbVie Inc, North Chicago, IL, USA.

Expert Opin Drug Deliv ; 20(2): 223-240, 2023 02.

Article en En | MEDLINE | ID: mdl-36632784

Asunto(s)

Productos Biológicos; Oftalmopatías; Humanos; Sistemas de Liberación de Medicamentos/métodos; Oftalmopatías/tratamiento farmacológico; Retina; Preparaciones Farmacéuticas; Soluciones Oftálmicas/uso terapéutico

Palabras clave

Anti-VEGF; biologics; formulation design; intravitreal injection; ocular drug delivery; ophthalmic disease; preclinical; retinal diseases; sustained drug delivery

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Productos Biológicos / Oftalmopatías Límite: Humans Idioma: En Revista: Expert Opin Drug Deliv Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google